WNK2 and hepatocellular carcinoma: A study revealed that MG53 exerts inhibitory effects on the malignant progression of hepatocellular carcinoma through its regulation of Ras-related C3 botulinum toxin substrate 1 (RAC1) ubiquitination and degradation while enhancing the chemosensitivity of hepatocellular carcinoma cells to sorafenib treatment by blocking the RAC1/mitogen-activated protein kinase signaling pathway (Ma et al., 2022).